ProQR Therapeutics BV Cash Flow Conversion Efficiency
ProQR Therapeutics BV cash flow conversion efficiency. Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has a cash flow conversion efficiency ratio of -0.156x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.40 Million) by net assets ($79.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ProQR Therapeutics BV (2013–2025)
Cash flow conversion efficiency of ProQR Therapeutics BV from 2013 to 2025. This chart illustrates how ProQR Therapeutics BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PRQR share price today for real-time trading data and today's change.
ProQR Therapeutics BV Cash Flow Conversion Ratio Explained
ProQR Therapeutics BV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ProQR Therapeutics BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProQR Therapeutics BV ranked by their cash flow conversion efficiency. Also see how much is ProQR Therapeutics BV worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Multikarya Asia Pacific Ray
JK:MKAP
|
0.080x |
|
TTFB Co Ltd
TWO:2729
|
0.118x |
|
Nextgreen Global Bhd
KLSE:7241
|
0.093x |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
-0.002x |
|
KOSKISEN OYJ EO 1
F:EZ8
|
0.040x |
|
Wildcat Resources Ltd
AU:WC8
|
-0.002x |
|
NorAm Drilling AS
F:TM9
|
0.094x |
|
Ndr Auto Components Limited
NSE:NDRAUTO
|
0.023x |
Annual Cash Flow Conversion Efficiency for ProQR Therapeutics BV (2013–2025)
The table below shows the annual cash flow conversion efficiency of ProQR Therapeutics BV from 2013 to 2025. Review PRQR FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.99 Million | $-52.79 Million | -0.910x | -129.40% |
| 2024-12-31 | $91.70 Million | $-36.39 Million | -0.397x | -184.21% |
| 2023-12-31 | $45.72 Million | $21.55 Million | 0.471x | +148.96% |
| 2022-12-31 | $71.17 Million | $-68.51 Million | -0.963x | -376.53% |
| 2021-12-31 | $128.76 Million | $-26.01 Million | -0.202x | +70.30% |
| 2020-12-31 | $69.19 Million | $-47.06 Million | -0.680x | -62.93% |
| 2019-12-31 | $105.33 Million | $-43.97 Million | -0.417x | -26.11% |
| 2018-12-31 | $92.69 Million | $-30.68 Million | -0.331x | +55.27% |
| 2017-12-31 | $47.22 Million | $-34.95 Million | -0.740x | -21.22% |
| 2016-12-31 | $56.05 Million | $-34.22 Million | -0.611x | -145.80% |
| 2015-12-31 | $97.55 Million | $-24.23 Million | -0.248x | -127.47% |
| 2014-12-31 | $132.38 Million | $-14.46 Million | -0.109x | -100.57% |
| 2013-12-31 | $-122.64K | $-2.33 Million | 19.015x | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more